Drugs / PIKA COVID-19 Vaccine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05305300 | Oct 2021 → May 2022 | COVID-19 | Yisheng Biopharma (Singapore) Pte. Ltd. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05463419 | Oct 2022 → Dec 2023 | — | Yisheng Biopharma (Singapore) Pte. Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PIKA COVID-19 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05463419 ↗ |
| Known as | PIKA coronavirus disease 2019 (COVID-19) vaccine | “This is a phase I, open-label, dose-escalation study at three dose levels (5 µg, 10 µg, and 20 µg) of the PIKA coronavirus disease 2019 (COVID-19) vaccine administered intramuscularly.” PMID 39525677 ↗ Oct 2024 |
| Modality | Vaccine | “PIKA-adjuvanted recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein subunit vaccine” PMID 39525672 ↗ Oct 2024 |
| Route | Intramuscular | “administered intramuscularly (IM)” NCT05305300 ↗ |